Health Care·Biotechnology·$26.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.41 | N/A | -80.55% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.41 | N/A | -80.55% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions. They highlighted their commitment to navigating these challenges effectively.
Management acknowledged the challenges faced this quarter.
They emphasized ongoing efforts to improve future performance.
BioNTech's earnings report shows a significant miss on EPS, reflecting ongoing challenges in the market. Despite this, the stock saw a slight increase of 0.68%, indicating some investor optimism or stabilization. The lack of revenue figures and guidance leaves uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HERSHEY CO
May 3, 2024